Physician profile
Mark A Kudes
NPI 1265448955
$4,376.67
in general payments reported to CMS, 2019-2025
33 companies · $918 in 2025
The $918 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $206 · 2021: $462 · 2022: $485 · 2023: $904 · 2024: $590 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,412.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $519.07 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $402.85 | 2019-2025 | |
| Amgen INC. | $370.32 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $329.47 | 2019-2025 | Brilinta, Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $290.43 | 2019-2024 | Xarelto |
| Edwards Lifesciences Corporation | $259.83 | 2019-2025 | Sapien 3 Ultra Resilia |
| Sanofi-Aventis U.S. LLC | $246.83 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $243.85 | 2021-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.80 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $186.74 | 2019-2025 | Camzyos, Eliquis |
| Daiichi Sankyo INC. | $184.69 | 2020-2025 | Injectafer |
| Biotronik INC. | $116.93 | 2024-2025 | Amvia Edge |
| Amarin Pharma, INC. | $101.17 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $88.08 | 2023-2025 | Evkeeza |
| Esperion Therapeutics, INC. | $86.44 | 2021-2025 | Nexletol |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $84.76 | 2021-2024 | (Ck4) Mcot |
| Novo Nordisk INC | $78.87 | 2023-2024 | Rybelsus, Ozempic |
| Atricure, INC. | $72.80 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $61.51 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $55.10 | 2019-2023 | Lifevest |
| Baxter Healthcare | $45.95 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Alnylam Pharmaceuticals INC. | $45.27 | 2024-2025 | Onpattro |
| Inspire Medical Systems, INC. | $44.88 | 2024-2025 | Inspire |
| Kiniksa Pharmaceuticals, LTD. | $43.94 | 2022-2023 | Arcalyst |
| Abbott Laboratories | $36.62 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Kiniksa Pharmaceuticals International, Plc | $31.88 | 2024 | Arcalyst |
| Medtronic Vascular, INC. | $24.99 | 2019 | |
| Boston Scientific Corporation | $21.81 | 2023 | Bodyguardian |
| Lilly USA, LLC | $18.63 | 2025 | Zepbound |
| Medtronic, INC. | $16.55 | 2021 | |
| Medicomp INC | $14.83 | 2024 | Telepatch Cardiac Monitor |
| Lantheus Medical Imaging, INC. | $12.49 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kudes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.